Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.

Key Stats

• Today's Range: $0.97 to $1.09
• 50-Day Range: $0.85 to $1.62
• 52-Week Range: $0.85 to $49.00
• Volume: 182,268 shs
• Average Volume: 716,335 shs
• Market Capitalization: $2.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

CTOR Stock Analysis - Frequently Asked Questions

How have CTOR shares performed this year?

Citius Oncology's stock was trading at $2.47 at the start of the year. Since then, CTOR stock has decreased by 60.4% and is now trading at $0.9781.
View the best growth stocks for 2024 here.

How do I buy shares of Citius Oncology?

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Citius Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CTOR
• CUSIP: N/A
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: 347-627-0058
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +206.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.25%
• Return on Assets: 3.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.24 per share
• Price / Cash Flow: 4.10
• Book Value: ($0.22) per share
• Price / Book: -4.45

Miscellaneous

• Outstanding Shares: 2,355,000
• Free Float: 1,816,000
• Market Cap: $2.30 million
• Optionable: N/A
• Beta: -0.21